[Frequency and clinical implications of lupus anticoagulant in patients with terminal chronic renal failure in hemodialysis].
The objective of the present study was to determine the frequency of lupus anticoagulant (LA), in patients with terminal chronic renal failure (TCRF), and its association with thrombotic events. Sixty three patients were separated into two groups: Group A, consisted of 32 patients under treatment with hemodialysis, and Group B was formed of 31 patients who were treated in a conservative manner. Presence of LA was found in 4 patients from Group A and none from Group B. Seven thrombotic events were registered, all in patients from Group A, and three of the episodes happened in 2 patients with LA, showing a statistically significant difference with LA negative patients from the same Group A (p < 0.001). Three of the LA positive patients suffered from type 2 diabetes and all of them had been under dialysis for less obtained by than 6 months. Vascular access was catheterization which means that 57.1% of patients with this type of procedure were positive for LA. The present results show a strong relationship between the presence of LA and thrombotic episodes in patients with TCRF, under hemodialysis with the use of catheter, instead of a permanent vascular access. Due to the fact that prolonged use of catheters for hemodialysis has been related to positive LA, it is advisable to screen patients under dialysis for the presence of this antibody, and to promote the prompt availability of a permanent vascular access, in order to prevent complications, such as thrombosis.
Fernández-Abreu
Mary C
MC
Servicio de Nefrología, Hospital General del Sur Dr. Pedro Iturbe, Venezuela. gjam3000@hotmail.com
Diez-Ewald
María
M
Briceño
Soledad
S
Torres-Guerra
Enrique
E
Rodríguez
Zulay
Z
Fernández
Nelson
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D001166:Arteriovenous Shunt, Surgical; D016022:Case-Control Studies; D002404:Catheterization / Q000009:adverse effects; D002408:Catheters, Indwelling; D003928:Diabetic Nephropathies / Q000150:complications; D005260:Female; D006801:Humans; D015994:Incidence; D007239:Infections / Q000150:complications; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000209:etiology / Q000628:therapy; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D006435:Renal Dialysis; D019851:Thrombophilia / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology*; D014687:Venezuela / Q000453:epidemiology
D016682:Lupus Coagulation Inhibitor